Parvinder Singh transformed Ranbaxy into a global pharmaceutical powerhouse, but the empire he built crumbled under his sons’ ...

Milwaukee's 2025 construction plans include mall redevelopments, housing, hotels, and more. Meanwhile, megaprojects flourish ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...

"The initial presentation typically includes dementia and neurological symptoms such as ataxia, myoclonus, and gait abnormalities as well as behavioral changes," Cetin and co-authors wrote. Sporadic ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

Silence Therapeutics plc's Zerlasiran has done well, but Eli Lilly's Muvalaplin is simply better. Read more about SLN stock ...

The U.S. Surgeon General issued an advisory that alcohol consumption is a leading preventable cause of cancer, calling for an update to warning labels on alcohol-containing beverages to now include ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy New Year, biotech ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...